Dasatinib (BMS-354825, SPRYCEL; Bristol-Myers Squibb, New York, USA) is a second-generation ATP-competitive inhibitor of a subset of protein tyrosine kinases, including abl, Src-family kinases (c-Src, Lck, Hck, Yes, Fgr, Lyn and Fyn), and the plateletderived growth factor family members c-kit and platelet-derived growth factor-a and -b. 1, 2 Dasatinib displays clinical activity in chronic myeloid leukaemia patients who develop resistance to or are intolerant to the frontline chronic myeloid leukaemia chemotherapeutic imatinib mesylate (STI571, Gleevec; Novartis, Basel, Switzerland). 3 Although designed to inhibit abl and/or Src protein kinases, tyrosine kinase inhibitors, like dasatinib and imatinib, show off-target effects. We have shown earlier that therapeutic concentrations of imatinib decrease osteoclast numbers and activity, at least in part through inhibition of the macrophage colony-stimulating factor (M-CSF) receptor, c-fms. 4, 5 Signalling through c-fms plays an essential role in the survival and activity of bone-resorbing osteoclasts, which act in conjunction with bone-forming osteoblasts to maintain skeletal health. In in vitro osteoclast cultures and animal models, such as op/op mice, an absence of signalling through c-fms results in an osteopetrotic phenotype because of deficient osteoclasts and osteoclast precursors. 6 Recent evidence suggests that dasatinib, like imatinib, may potentially inhibit signal transduction through c-fms. In cultures of M-CSF-dependent Ba/F3 cells that ectopically expressed human c-fms, cell numbers were decreased by dasatinib treatment. 2 In light of this observation, this study examined whether dasatinib could modulate osteoclast formation and/or activity, and whether any such effects were attributable to an inhibition of c-fms signal transduction.
We examined the effect of dasatinib on osteoclast formation and activity in human and murine systems in vitro. Human CD14 þ mononuclear cells (huCD14 þ ) were isolated from the peripheral blood of healthy volunteers using Percoll gradient separation and a MACS negative selection monocyte kit (Miltenyi Biotech, Bergisch Gladbach, Germany). The cells were cultured with recombinant human (rh)M-CSF and rhRANKL, to induce osteoclastogenesis, supplemented with dasatinib or vehicle. After 14 days of culture, a significant decrease in the number of tartrate-resistant acid phosphatasepositive multinucleated cells was observed at 20 nM dasatinib (Po0.001; IC 50 ¼ 10.5 nM; Figure 1a ). Murine osteoclastogenesis assays were established by explanting mouse bone marrow from the tibiae and femora of C57 BL/6 mice. Cells were incubated overnight at 37 1C in 5% CO 2 , to allow stromal cells to adhere, and non-adherent mouse bone marrow cells (mBM) were collected and used as monocyte/macrophage osteoclast precursor cells. In mBM cultures treated with rhM-CSF and rhRANKL for 6 days, osteoclast numbers were decreased at 10 nM dasatinib (Po0.01; Figure 1b ) and osteoclast formation was completely abrogated at 20 nM dasatinib (IC 50 ¼ 8.0 nM; Figure 1b ). Osteoclast size was also substantially reduced in cultures treated with 10 nM dasatinib compared with controls, in both human and murine systems (Figure 1c) .
The effect of dasatinib on osteoclast activity was also assessed in huCD14 þ and mBM cultures established on calcium phosphate-coated slides. A significant inhibition of resorption was observed at X1.25 nM dasatinib in huCD14 þ cultures (Po0.001; IC 50 ¼ 2.4 nM; Figures 1d and f), and at X2.5 nM dasatinib in mBM cultures (Po0.05; IC 50 ¼ 3.5 nM; Figures 1e and f), relative to vehicle controls. Thus, therapeutically relevant concentrations of dasatinib (C max ¼ 110.0 nM) 7 significantly reduced the formation and activity of osteoclasts from huCD14 þ and mBM at IC 50 concentrations of p10 nM dasatinib.
As dasatinib may affect osteoclastogenesis through inhibition of c-fms, we investigated whether dasatinib could specifically inhibit c-fms kinase activity. Initially, the effect of dasatinib on c-fms-dependent cell proliferation was examined using FDC-P1 cells expressing c-fms protein (FDC-cfms). 4 FDC-P1 cells are dependent on interleukin-3 for proliferation and are also rendered M-CSF-responsive by transfection with a c-fms expression construct. The resulting cells are dependent on either interleukin-3 or M-CSF for survival and proliferation. Treatment of rhM-CSF-stimulated FDC-cfms cells with dasatinib for 24 h significantly decreased cell numbers at concentrations of X50 nM (Po0.001; IC 50 ¼ 57.8 nM; Figure 2a ). In contrast, the proliferation of FDC-P1 cells or FDC-cfms cells cultured in the presence of interleukin-3 (0.5 ng/ ml) was not significantly affected by dasatinib treatment at concentrations up to 100 nM (P ¼ 0.9012 and P ¼ 0.2008, respectively; Figure 2a ).
To determine whether dasatinib treatment could also inhibit the M-CSF-dependent proliferation/survival of primary bone marrow cells, the effect of dasatinib on mBM cells was assessed using a WST-1 assay (Tanaka, Madison, WI, USA). The relative number of viable, metabolically active cells per well, as detected by the quantification of mitochondrial dehydrogenase Figure 1 Dasatinib inhibits the formation and activity of human and murine osteoclast-like cells in vitro. (a) huCD14 þ were cultured on 96-well plates or calcium-coated osteologic slides (BD Biosciences, Bedford, MA, USA) in media containing recombinant human (rh) macrophage colonystimulating factor (M-CSF) (25 ng/ml; day 0-21), rhRANKL (25 ng/ml; day 8-21) and dasatinib (containing 0.05% dimethylsulphoxide (DMSO) vehicle) or vehicle alone. (b) Mouse bone marrow (mBM) cells were cultured on 96-well plates or calcium-coated slides in media containing rhM-CSF (75 ng/ml). Following overnight adhesion, the cultures were treated with media containing rhM-CSF (75 ng/ml), rhRANKL (75 ng/ml) and the indicated doses of dasatinib (containing 0.05% DMSO vehicle) or vehicle alone. After 14 days (huCD14 þ ; a) or 6 days (mBM; b) cultures were stained for tartrate-resistant acid phosphatase using a commercial kit and tartrate-resistant acid phosphatase-positive cells with three or more nuclei were counted. Representative photographs are shown (c). Arrows indicate tartrate-resistant acid phosphatase-positive, multinucleated cells. Scale bars: 200 mm. After 21 days (huCD14 þ ; d) or 9 days (mBM; e) of culture, the calcium-coated slides were stained with von Kossa silver stain and the area of substrate resorbed was calculated. Representative photographs are shown (f). Graphs depict mean ± s.e.m. of quadruplicate wells of a representative of three (a) or four (d) independent experiments and mean ± s.e.m. of three independent experiments (b and e). *Po0.05, **Po0.01, ***Po0.001; one-way analysis of variance with Dunnett's post-test.
Letters to the Editor activity, was significantly decreased by dasatinib (2.5-40 nM; Po0.01) relative to controls after 72 h (IC 50 ¼ 5.0 nM; Figure 2b ). In contrast, the proliferation of the mouse monocyte/macrophage-like cell line RAW 264.7, which is not dependent on M-CSF for cell survival, was not affected by dasatinib treatment (P ¼ 0.4894; Figure 2b ). These data strongly suggest that the proliferation/survival of M-CSF-dependent, but not M-CSFindependent, cells is inhibited by dasatinib. These findings support previously published data indicating that the proliferation of Ba/F3-c-fms cells was inhibited by dasatinib.
To investigate whether dasatinib could directly inhibit c-fms activation in primary human and murine monocyte/macrophage-lineage cells, the effect of dasatinib pretreatment on M-CSF-mediated c-fms activation was examined by western blot. Cultures of huCD14 þ and mBM that were serum starved for 90-120 min displayed no c-fms phosphorylation (Figures 2c and  d) . In contrast, starved cultures stimulated with M-CSF for 5 min showed rapid induction of c-fms phosphorylation. Pretreatment of cultures with dasatinib inhibited M-CSF-induced phosphorylation of c-fms at concentrations of X5 nM in both huCD14 þ and mBM (Figures 2c and d) . A strong association between the concentration at which dasatinib inhibits osteoclast resorptive activity (IC 50 ¼ 2.4 nM (huCD14 þ ) and 3.5 nM (mBM)) and c-fms signal transduction (IC 50 ¼ 4.6 nM (huCD14 þ ) and 3.0nM (mBM)) was observed. This suggests that the inhibition of osteoclast activity in these cultures may be attributable, at least in part, to inhibition of c-fms kinase activity. However, at this stage, the possibility that non-specific toxicity contributes to the inhibitory effects of dasatinib on osteoclasts cannot be ruled out.
In addition, dasatinib may also affect osteoclastogenesis through inhibition of the non-receptor tyrosine kinase c-Src. c-Src is critical for normal osteoclast activity, as is shown in c-SrcÀ/À mice, which are severely osteopetrotic due to an absence of osteoclast activity rather than a reduction in osteoclast number. [8] [9] [10] This is thought to be primarily due to the defective osteoclast actin ring and sealing zone formation following inhibition of signalling by integrins such as a v b 3 . 8, 9 The effect of dasatinib on c-Src phosphorylation in osteoclast precursors was examined by western blot. Dasatinib treatment decreased basal levels of Src phosphorylation at doses of X20 nM in both huCD14 þ and mBM (IC 50 ¼ 15.5 and 17.15, respectively; Figures 2c-f) . These results suggest that, under the culture conditions used in the experiments reported here, dasatinib treatment inhibits c-Src phosphorylation at concentrations higher than those that inhibit osteoclast activity in mBM and huCD14 þ .
In summary, our results suggest that dasatinib can inhibit osteoclast formation and activity in vitro, at least in part through an inhibition of c-fms signal transduction. Inhibition of osteoclast activity, if not corrected by a decrease in osteoblast activity, may lead to an overall increase in bone volume. To this end, current evidence suggests that patients undergoing treatment with imatinib mesylate exhibit dysregulated bone remodelling, resulting in an overall increase in trabecular bone volume. [11] [12] [13] This is thought to result from an inhibition of osteoclast activity and a concomitant activation of osteoblast activity by imatinib, through inhibition of c-fms and PDGFR, respectively. 5, 11 Although it is unknown whether dasatinib alters the mineralization activity of osteoblasts, it could be predicted to promote osteogenesis as it is a potent inhibitor of PDGFR. If this is the case, a decrease in osteoclast activity and a concurrent increase in osteoblast activity by dasatinib may result in decoupling of the bone remodelling process. This hypothesis awaits further investigation in suitable animal models of normal bone remodelling. These studies also suggest the need to monitor skeletal remodelling in patients receiving dasatinib, as has been prescribed for imatinib mesylate. 11 Furthermore, it highlights the potential application of dasatinib therapy in cases of pathologies characterized by increased osteoclast activity, such as in osteoporosis, osteoarthritis, bone metastatic breast cancer and prostate cancer, and multiple myeloma. Essential thrombocythemia (ET) is mainly characterized by the abnormal proliferation of a malignant megakaryocytic clone and by persistent thrombocytosis. Recently, a JAK2 mutation (JAK2V617F) has been reported in ET and other myeloproliferative neoplasms. In particular, 40-60% of ET patients harbor this mutation and a substantial proportion of them are heterozygous with allele burden below 50%.
1 JAK2V617F mutation distinguishes the disease into two biologically distinct subtypes with the V617F-positive subgroup exhibiting many laboratory and clinical similarities to polycythemia vera. Furthermore, 50
